NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care for neurological disorders, announced today that it will release its financial results for the fiscal third quarter ended June 30, 2026, before market open on Thursday, August 13, 2026. The company will also host an investor conference call and webcast at 8:30 a.m. Eastern time that same day to discuss the results and provide a corporate update.
The announcement comes as NeuroOne continues to advance its portfolio of FDA-cleared products, including the Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These technologies are designed to offer minimally invasive, high-definition solutions for diagnosing and treating neurological conditions, potentially reducing hospitalizations, lowering costs, and improving patient outcomes.
Investors and interested parties can participate in the conference call by dialing 888-506-0062 (toll-free within the U.S.) or 973-528-0011 (international) and using participant access code 549778. A webcast of the call will also be available via the company's investor relations website. Participants are encouraged to join at least five minutes before the start of the call.
A telephone replay of the call will be available through Thursday, August 27, 2026, by dialing 877-481-4010 (U.S.) or 919-882-2331 (international) with replay passcode 54304. Additionally, a webcast replay will be accessible on the company's website through August 13, 2027.
NeuroOne's focus on innovation extends beyond its current product lineup. The company is actively engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. These initiatives underscore NeuroOne's commitment to expanding its technology platform and addressing a broader range of neurological and pain-related conditions.
This earnings announcement is significant for shareholders and industry observers as it will provide insights into the company's financial performance and strategic direction. With a growing portfolio of FDA-cleared products and ongoing R&D efforts, NeuroOne is positioning itself as a key player in the neuromodulation and neurodiagnostic space. The upcoming conference call will offer a valuable opportunity for stakeholders to gain clarity on the company's progress and future plans.
For more information about NeuroOne, visit nmtc1.com.
